Treatment options for central retinal artery occlusion

Current Treatment Options in Neurology

Volumn 15, Issue 1, 2013, Pages 63-77

  Cugati, Sudha ^a   Varma, Daniel D ^b   Chen, Celia S ^c   Lee, Andrew W ^b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

Author keywords

Central retinal artery occlusion; Intraocular pressure; Neovascularization; Thrombolysis; Thrombolytic therapy; Treatment; Vasodilators

Indexed keywords

ACETAZOLAMIDE; ALTEPLASE; AMINOPHYLLINE; ANTICOAGULANT AGENT; ANTIGLAUCOMA AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BROMOCRIPTINE; CABERGOLINE; CARBOGEN; CISAPRIDE; DIHYDROERGOTAMINE; ERGOTAMINE; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; LURASIDONE; MANNITOL; METHENAMINE; METHYLERGOMETRINE; METHYLPREDNISOLONE; METHYSERGIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; THEOPHYLLINE; TISSUE PLASMINOGEN ACTIVATOR; TOBRAMYCIN; WARFARIN;

ACIDOSIS; AGRANULOCYTOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANOREXIA; ANXIETY; APLASTIC ANEMIA; ARTICLE; ASEPTIC MENINGITIS; BLEEDING; BLOOD CLOT LYSIS; BLURRED VISION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN HERNIA; BRAIN ISCHEMIA; CENTRAL RETINA ARTERY OCCLUSION; CHOLECYSTITIS; CONFUSION; CONGESTIVE HEART FAILURE; CONJUNCTIVITIS; CONSTIPATION; CONVULSION; DEHYDRATION; DEPRESSION; DIARRHEA; DIET; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DYSPNEA; EDEMA; ELECTROLYTE DISTURBANCE; EPISTAXIS; ERYTHRODERMA; FAINTNESS; FLACCID PARALYSIS; FLUSHING; GLUCOSURIA; HEARING DISORDER; HEMATURIA; HUMAN; HYPERBARIC OXYGEN; HYPERTENSION; HYPOTENSION; INTRAOCULAR PRESSURE; LARYNX EDEMA; LEUKOPENIA; LIFESTYLE; LIVER DISEASE; LOADING DRUG DOSE; MALAISE; MASSAGE; MELENA; METHEMOGLOBINEMIA; NAIL DISEASE; NAUSEA; NAUSEA AND VOMITING; NEODYMIUM YAG LASER; NERVOUSNESS; NONHUMAN; NOSE OBSTRUCTION; OTALGIA; OXYGEN BLOOD LEVEL; PARACENTESIS; PARESTHESIA; PHLEBITIS; PHOTOSENSITIVITY; POLYURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA EDEMA; RETINA NEOVASCULARIZATION; RISK FACTOR; SCOTOMA; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TINNITUS; UNSTABLE ANGINA PECTORIS; URINE RETENTION; URTICARIA; VITRECTOMY; VOMITING; XEROSTOMIA;

EID: 84873089703     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0202-9     Document Type: Article

References (73)

1. Graefes AV. Ueber Embolie der Arteria centralis retinae als Ursache plotzlicher Erblindung. Arch Ophthalmol;5:136-157
2. Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The incidence of central retinal artery occlusion in Olmsted County, Minnesota. Am J Ophthalmol. 2011;152:820-3.
3. Rumelt S, Brown GC. Update on treatment of retinal arterial occlusions. Curr Opin Ophthalmol. 2003;14:139-41.
4. Hayreh SS, Zimmerman MB. Central retinal artery occlusion: visual outcome. Am J Ophthalmol. 2005;140:376-91.
5. Lorentzen S. Incidence of cilioretinal arteries. Acta Ophthalmol. 1970;48:518-24.
6. Hayreh S. Acute retinal arterial occlusive disorders. Progr Retin Eye Res. 2011;30:359-94.
7. Hayreh S. A Study of the Central Artery of the Retina in Human Beings in its Intra-orbital and Intra-neural Course: Thesis for Master of Surgery, Panjab University, India, 1958. Back to cited text, 1958.
8. Mangat HS. Retinal artery occlusion. Surv Ophthalmol. 1995;40:145-56.
9. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive disorders. Progr Retin Eye Res. 2005;24:493-519.
10. Hayreh S, Kolder H, Weingeist T. Central retinal artery occlusion and retinal tolerance time. Ophthalmology. 1980;87:75.
11. Chen CS, Lee AW. Management of acute central retinal artery occlusion. Nat Clin Pract Neurol. 2008;4:376-83.
12. Rudkin A, Lee A, Chen C. Vascular risk factors for central retinal artery occlusion. Eye. 2009;24:678-81.
13. Schmidt DP, Schulte-Mönting J, Schumacher M. Prognosis of central retinal artery occlusion: local intraarterial fibrinolysis versus conservative treatment. Am J Neuroradiol. 2002;23:1301-7.
14. Kline L. The natural history of patients with amaurosis fugax. Ophthalmol Clinics of N Am. 1996;9:351-8.
15. Savino PJ, Glaser JS, Cassady J. Retinal stroke: is the patient at risk? Arch Ophthalmol. 1977;95:1185.
16. Augsburger J, Magargal L. Visual prognosis following treatment of acute central retinal artery obstruction. Br J Ophthalmol. 1980;64:913-7.
17. Pfaffenbach D, Hollenhorst R. Morbidity and survivorship of patients with embolic cholesterol crystals in the ocular fundus. Trans Am Ophthalmol Soc. 1972;70:337.
18. Ffytche T. A rationalization of treatment of central retinal artery occlusion. Trans Ophthalmol Soc U K. 1974;94:468-79.
19. Wang FM, Henkind P. Visual system involvement in giant cell (temporal) arteritis. Surv Ophthalmol. 1979;23:264-71.
20. McBrien D, Bradley R, Ashton N. The nature of retinal emboli in stenosis of the internal carotid artery. Lancet. 1963;281:697-9.
21. Cogan DG, Kuwabara T, Moser H. Fat emboli in the retina following angiography. Arch Ophthalmol. 1964;71:308-13.
22. David NJ, Lintworth GK, Friedberg SJ, Dillon M. Fetal atheromatous cerebral embolism associated with bright plaques in the retinal arterioles. Report of a case. Neurology. 1963;13:708-13.
23. Greven CM, Slusher MM, Weaver RG. Retinal arterial occlusions in young adults. Am J Ophthalmol. 1995;120:776-83.
24. Schmidt D, Hetzel A, Geibel-Zehender A, Schulte-Monting J. Systemic diseases in non-inflammatory branch and central retinal artery occlusion-an overview of 416 patients. Eur J Med Res. 2007;12:595-603.
25. Hayreh SS, Piegors DJ, Heistad DD. Serotonin-induced constriction of ocular arteries in atherosclerotic monkeys: implications for ischemic disorders of the retina and optic nerve head. Arch Ophthalmol. 1997;115:220-8.
26. Hjermann I, Velve BK, Holme I, Leren P. Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men. Lancet. 1981;2:1303-10.
27. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106:388-91.
28. Sottilotta G, Oriana V, Latella C, et al. Role of hyperhomocystinemia in retinal vascular occlusive disease. Clin Appl Thromb Hemost. 2007;13:104-7.
29. Hayreh SS, Zimmerman MB, Kimura A, Sanon A. Central retinal artery occlusion: retinal survival time. Exp Eye Res. 2004;78:723-36.
30. Chen CS, Lee AW, Campbell B, et al. Efficacy of intravenous tissue-type plasminogen activator in central retinal artery occlusion. Stroke. 2011;42:2229-34.
31. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I, Baatz H. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion. Am J Ophthalmol. 2008;146:700-6. e701.
32. Beatty S, Eong KGA. Local intra-arterial fibrinolysis for acute occlusion of the central retinal artery: a meta-analysis of the published data. Br J Ophthalmol. 2000;84:914-6.
33. Landa E, Rehany U, Rumelt S. Visual functions following recovery from non-arteritic central retinal artery occlusion. Ophthalmic Surg Laser Imag. 2004;35:103.
34. Mueller AJ, Neubauer AS, Schaller U, Kampik A. Evaluation of minimally invasive therapies and rationale for a prospective randomized trial to evaluate selective intra-arterial lysis for clinically complete central retinal artery occlusion. Arch Ophthalmol. 2003;121:1377-81.
35. Incandela L, Cesarone M, Belcaro G, et al. Treatment of vascular retinal disease with pentoxifylline: a controlled, randomized trial. Angiology. 2002;53:31-4.
36. Fraser SG, Adams W. Interventions for acute non-arteritic central retinal artery occlusion. Cochrane Database Syst Rev 2009;1.
37. Arend O, Harris A, Martin BJ, Holin M, Wolf S. Retinal blood velocities during carbogen breathing using scanning laser ophthalmoscopy. Acta Ophthalmol. 1994;72:332-6.
38. Harino S, Grunwald JE, Petrig BJ, Riva CE. Rebreathing into a bag increases human retinal macular blood velocity. Br J Ophthalmol. 1995;79:380-3.
39. Deutsch TA, Read JS, Ernest JT, Goldstick TK. Effects of oxygen and carbon dioxide on the retinal vasculature in humans. Arch Ophthalmol. 1983;101:1278-80.
40. Atebara NH, Brown GC, Cater J. Efficacy of anterior chamber paracentesis and Carbogen in treating acute nonarteritic central retinal artery occlusion. Ophthalmology. 1995;102:2029-34. discussion 2034-2025.
41. Aisenbrey S, Krott R, Heller R, Krauss D, Rössler G, Heimann K. Hyperbaric oxygen therapy in retinal artery occlusion. Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft. 2000;97:461-7.
42. Menzel-Severing J, Siekmann U, Weinberger A, Roessler G, Walter P, Mazinani B. Early hyperbaric oxygen treatment for nonarteritic central retinal artery obstruction. Am J Ophthalmol. 2012;153:454-9.
43. Cope A, Eggert J, O'Brien E. Retinal artery occlusion: visual outcome after treatment with hyperbaric oxygen. Diving Hyperb Med. 2011;41:135-8.
44. Hertzog L, Meyer G, Carson S, Strauss M, Hart G. C treated with hyperbaric oxygen. Undersea Hyperb Med. 1992.
45. Weiss JN. Hyperbaric oxygen treatment of nonacute central retinal artery occlusion. Undersea Hyperb Med. 2010;37:167-72.
46. Anderson Jr B, Saltzman HA, Heyman A. The effects of hyperbaric oxygenation on retinal arterial occlusion. Arch Ophthalmol. 1965;73:315-9.
47. Butler Jr F, Hagan C, Murphy-Lavoie H. Hyperbaric oxygen therapy and the eye. Undersea Hyperb Med. 2008:333-387
48. Rumelt S, Dorenboim Y, Rehany U. Aggressive systematic treatment for central retinal artery occlusion. Am J Ophthalmol. 1999;128:733-8.
49. Beatty S, Eong KGA. Acute occlusion of the retinal arteries: current concepts and recent advances in diagnosis and management. Emerg Med J. 2000;17:324-9.
50. Hausmann N. High dose steroid bolus given for occlusion of central retinal artery: author's reply. Br Med J. 1992;304:506-7.
51. Pandit JC, Tiamiyu F. High dose steroid bolus given for occlusion of central retinal artery. BMJ: Br Med J. 1992;304:506-7.
52. Biousse V, Calvetti O, Bruce BB, Newman NJ. Thrombolysis for central retinal artery occlusion. J Neuro Ophthalmol. 2007;27:215-30.
53. Noble J, Weizblit N, Baerlocher M, Eng K. Intra-arterial thrombolysis for central retinal artery occlusion: a systematic review. Br J Ophthalmol. 2008;92:588-93.
54. Aldrich EM, Lee AW, Chen CS, et al. Local Intraarterial fibrinolysis administered in aliquots for the treatment of central retinal artery occlusion. Stroke. 2008;39:1746-50.
55. Zhang X, Ji X, Luo Y, et al. Intra-arterial thrombolysis for acute central retinal artery occlusion. Neurol Res. 2009;31:385-9.
56. Schumacher M, Schmidt D, Jurklies B, et al. Central retinal artery occlusion: local intra-arterial fibrinolysis versus conservative treatment, a multicenter randomized trial. Ophthalmology 2010;117:1367-1375. e1361.This randomised multicentre study compares the treatment outcomes of conventional treatment versus intra-arterial tPA in patients with CRAO.
57. Lindsberg PJ, Mattle HP. Therapy of basilar artery occlusion a systematic analysis comparing intra-arterial and intravenous thrombolysis. Stroke. 2006;37:922-8.
58. Arnold M, Koerner U, Remonda L, et al. Comparison of intra-arterial thrombolysis with conventional treatment in patients with acute central retinal artery occlusion. J Neurol Neurosurg Psychiatr. 2005;76:196-9.
59. Biousse V. Thrombolysis for acute central retinal artery occlusion: is it time? Am J Ophthalmol. 2008;146:631.
60. Feltgen N, Neubauer A, Jurklies B, et al. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no. 1. Graefes Arch Clin Exp Ophthalmol. 2006;244:950-6.
61. Genentech. (2011). Activase, Alteplase, a recombinant tissue plasminogen activator. Available: http://www.gene.com/gene/products/information/ cardiovascular/activase/. Last accessed 16/8/12.
62. Derex L, Nighoghossian N. Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update. J Neurol Neurosurg Psychiatr. 2008;79:1093.
63. PDR Staff. 2004 Red Book Pharmacy's Fundamental Reference. 2004th ed. Montvale: Thomson Healthcare; 2004. p183.
64. Fagan S, Morgenstern L, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology. 1998;50:883-90.
65. Demaerschalk BM, Hwang HM, Leung G. Cost analysis review of stroke centers, telestroke, and rt-PA. Am J Manag Care. 2010;16:537.
66. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
67. Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke. 2005;36:2500-3.
68. Reynard M, Hanscom TA. Neodymium: yttrium-aluminum-garnet laser arteriotomy with embolectomy for central retinal artery occlusion. Am J Ophthalmol. 2004;137:196-8.
69. Haritoglou C, Wolf A, Ulbig MW. Laser embolectomy for central retinal artery occlusion. Ophthalmologe. 2010;107:465-7.
70. Tang WM, Topping TM. Vitreous surgery for central retinal artery occlusion. Arch Ophthalmol. 2000;118:1586-7.
71. Peyman GA, Gremillion CM. Surgical removal of a branch retinal artery embolus: a case report. Int Ophthalmol. 1990;14:295-8.
72. Garcia-Arumi J, Martinez-Castillo V, Boixadera A, Fonollosa A, Corcostegui B. Surgical embolus removal in retinal artery occlusion. Br J Ophthalmol. 2006;90:1252-5.
73. Rudkin AK, Lee AW, Chen CS. Ocular neovascularization following central retinal artery occlusion: prevalence and timing of onset. Eur J Ophthalmol. 2010;20:1042-6.